CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and…